ライフサイエンスコーパス: second primary malignancy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ients, increased 18F-FDG uptake identified a second primary malignancy.

2 ears of follow-up and to explore the risk of second primary malignancies.

3 We investigated the long-term risk of second primary malignancy after chemotherapy for Hodgkin

4 Second primary malignancies and premature death are a co

5 associated with a small increase in risk of second primary malignancies and with increased risk of p

6 ce of all second primary malignancies, solid second primary malignancies, and haematological second p

7 ond primary malignancies, and haematological second primary malignancies, and were analysed by a one-

8 Cumulative incidences of all second primary malignancies at 5 years were 6.9% (95% CI

9 The cumulative incidence of second primary malignancies at 60 months after trial ent

10 The cumulative incidence rate of a second primary malignancy before disease progression was

11 second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact

12 ce treatment, date of first relapse, date of second primary malignancy diagnosis, type of second prim

13 increased risk of developing haematological second primary malignancies, driven mainly by treatment

14 There is no emerging safety signal for second primary malignancies following VMP.

15 sion and overall survival and an increase in second primary malignancies for lenalidomide at a median

16 ene may be associated with increased risk of second primary malignancies in glioma patients.

17 Lenalidomide has been linked to second primary malignancies in myeloma.

18 dicating premalignant lesions and preventing second primary malignancies in patients cured of squamou

19 smani et al provide important information on second primary malignancies in patients treated with tha

20 e available data to compare the incidence of second primary malignancies in patients with and without

21 an increased awareness of the possibility of second primary malignancies in patients with thymoma.

22 Three haematological and five solid tumour second primary malignancies in the placebo group were in

23 %) haematological and nine (4%) solid tumour second primary malignancies in the placebo group.

24 ficantly associated with the occurrence of a second primary malignancy in the same patient.

25 ncrease in haematological adverse events and second primary malignancies, lenalidomide maintenance th

26 l cancer (n = 7), lack of follow-up (n = 4), second primary malignancy (n = 3), or chemotherapy befor

27 halan significantly increased haematological second primary malignancy risk versus melphalan alone (H

28 24]; p=0.76) did not increase haematological second primary malignancy risk versus melphalan alone.

29 of interest were cumulative incidence of all second primary malignancies, solid second primary malign

30 Second primary malignancies (SPM) were observed in 8 pat

31 ll carcinoma (HNSCC) are at elevated risk of second primary malignancies (SPM), most commonly of the

32 e rate (IR, events per 100 patient-years) of second primary malignancies (SPMs) was 3.62.

33 Evaluation for the development of second primary malignancies (SPMs) was conducted, and no

34 apy is associated with a higher incidence of second primary malignancies (SPMs), including both hemat

35 I 0.62-2.00]; p=0.72), and of haematological second primary malignancies were 3.1% (95% CI 1.9-4.3) a

36 Cumulative 5-year incidences of solid second primary malignancies were 3.8% (95% CI 2.7-4.9) i

37 Data on second primary malignancies were collected by individual

38 (8%) haematological and 14 (6%) solid tumour second primary malignancies were diagnosed after randomi

39 15 second primary malignancies were reported in 12 patients

40 Eight patients developed 11 second primary malignancies with an excess frequency of

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。